Quick Answer
Akebia Therapeutics, Inc. reported Total Revenue of $236.20 million for fiscal year 2025.
Akebia Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $236.20M +47.5% |
$160.18M -17.7% |
$194.62M -33.5% |
$292.48M +36.9% |
$213.58M -27.7% |
$295.31M -11.8% |
| Revenue (ASC 606) | $236.20M +47.5% |
$160.18M -17.7% |
$194.62M -33.5% |
$292.48M +36.9% |
$213.58M -27.7% |
$295.31M -11.8% |
| Net Income | -$5.34M +92.3% |
-$69.41M -33.7% |
-$51.92M +44.9% |
-$94.23M +66.7% |
-$282.84M +26.2% |
-$383.46M -37.1% |
| Diluted EPS | -$0.02 +93.9% |
-$0.33 -17.9% |
-$0.28 +46.2% |
-$0.52 +69.4% |
-$1.70 +38.6% |
-$2.77 -17.4% |
| Total Assets | $376.56M +70.6% |
$220.67M -8.7% |
$241.70M -32.1% |
$356.05M -32.3% |
$525.55M -18.4% |
$644.14M -16.5% |
| Cash and Equivalents | $184.84M +256.4% |
$51.87M +20.8% |
$42.92M -52.6% |
$90.47M -39.6% |
$149.80M -34.5% |
$228.70M +55.1% |
| Long-Term Debt | $48.25M +24.7% |
$38.69M +125.2% |
$17.18M -49.6% |
$34.08M | $0.00 -100.0% |
$96.38M +27.1% |
| Stockholders Equity | $32.61M +166.3% |
-$49.19M -60.8% |
-$30.58M -684.8% |
$5.23M -92.9% |
$74.01M -70.1% |
$247.62M -37.3% |
| R&D Expense | $62.36M +65.6% |
$37.65M -40.3% |
$63.08M -51.5% |
$129.99M -12.1% |
$147.85M -32.3% |
$218.49M -32.4% |
| Operating Income | $23.50M +146.6% |
-$50.47M -9.1% |
-$46.26M +42.7% |
-$80.78M +69.6% |
-$265.32M +29.5% |
-$376.44M -31.5% |
| Shares Outstanding | 265.42M +18.0% |
224.85M +15.6% |
194.58M +5.7% |
184.14M +4.0% |
177.00M +19.5% |
148.07M +21.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $58.77M | +57.0% | -5.9% |
| Revenue (ASC 606) | September 30, 2025 | $58.77M | +57.0% | -5.9% |
| Net Income | September 30, 2025 | $540.0K | +102.7% | +118.6% |
| Diluted EPS | September 30, 2025 | $0.00 | +100.0% | — |
| Total Assets | September 30, 2025 | $364.15M | +75.8% | +5.4% |
| Cash and Equivalents | September 30, 2025 | $166.44M | +389.3% | +21.2% |
| Long-Term Debt | September 30, 2025 | $47.64M | +24.2% | +1.2% |
| Stockholders Equity | September 30, 2025 | $41.59M | +182.5% | +42.3% |
| R&D Expense | September 30, 2025 | $14.94M | +76.1% | +35.7% |
| Operating Income | September 30, 2025 | $4.45M | +135.6% | -68.4% |
| Shares Outstanding | September 30, 2025 | 265.23M | +25.4% | +0.8% |
- Akebia Therapeutics, Inc. reported Total Revenue of $236.20 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +47.5% in Total Revenue compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Revenue (ASC 606) of $236.20 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +47.5% in Revenue (ASC 606) compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Net Income of -$5.34 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +92.3% in Net Income compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +93.9% in Diluted EPS compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Total Assets of $376.56 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +70.6% in Total Assets compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Cash and Equivalents of $184.84 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +256.4% in Cash and Equivalents compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Long-Term Debt of $48.25 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +24.7% in Long-Term Debt compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Stockholders Equity of $32.61 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +166.3% in Stockholders Equity compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported R&D Expense of $62.36 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +65.6% in R&D Expense compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Operating Income of $23.50 million for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +146.6% in Operating Income compared to the prior fiscal year.
- Akebia Therapeutics, Inc. reported Shares Outstanding of 265.42 million shares for fiscal year 2025.
- Akebia Therapeutics, Inc. showed an increase of +18.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: